论文部分内容阅读
目的:观察长春瑞滨(NVB)联合洛铂(LBP)组成NL方案治疗晚期乳腺癌的疗效和不良反应。方法:从2004年1月~2005年10月,采用NVB加LBP的联合化疗方案治疗晚期乳腺癌33例,LBP30mg/m2,第1天,静脉滴注3小时;NVB25mg/m2,第1、8天,静脉滴注30分钟,21天为1周期。结果:全组33例共完成105个周期,中位3周期(2~4周期),均可评价疗效。获CR1例,PR13例,SD11例,PD8例,RR为42·4%,肿瘤控制率DCR(CR+PR+SD)为75·8%,中位缓解期为4个月(1~17个月)。主要不良反应为骨髓抑制,其中Ⅲ~Ⅳ度粒细胞减少发生率为57·6%,Ⅲ度血小板减少发生率为9·1%;非血液学毒性轻微,可以耐受。结论:洛铂联合长春瑞滨组成NL方案治疗局部晚期及转移性乳腺癌疗效较好,不良反应可以耐受,在加强支持治疗(应用造血因子)的基础上,可以考虑作为二线治疗或解救化疗方案。
Objective: To observe the curative effect and adverse reactions of vinorelbine (NVB) combined with lobaplatin (LBP) composed of NL regimen in the treatment of advanced breast cancer. Methods: From January 2004 to October 2005, 33 patients with advanced breast cancer were treated with combination therapy of NVB plus LBP, LBP30mg / m2, intravenous drip on the first day for 3 hours, NVB25mg / m2, Day, intravenous infusion of 30 minutes, 21 days for a cycle. Results: The whole group of 33 patients completed a total of 105 cycles, the median of 3 cycles (2 to 4 cycles), can evaluate the efficacy. Among them, CR1, PR13, SD11 and PD8 had RR of 42.4%, and the tumor control rate was DCR (CR + PR + SD) 75.8%. The median remission was 4 months (range 1-17) month). The main adverse reactions were myelosuppression. The incidence of Ⅲ ~ Ⅳ neutropenia was 57.6%, and the incidence of Ⅲ thrombocytopenia was 9.1%. The non-hematologic toxicity was tolerable. Conclusion: The combination regimen of vinorelbine and vinorelbine in the treatment of locally advanced and metastatic breast cancer has good efficacy and adverse reactions can be tolerated. On the basis of strengthening supportive therapy (hematopoietic factor), it can be considered as second-line therapy or rescue chemotherapy Program.